Approaches to optimal dosing of vitamin k antagonists

Seminars in Thrombosis and Hemostasis

Volumn 38, Issue 7, 2012, Pages 667-672

  Witt, Danielm ^a  

^a Clinical Pharmacy Research and Applied Pharmacogenomics   (United States)

Author keywords

anticoagulation; international normalized ratio; vitamin K antagonists; warfarin

Indexed keywords

ANTIVITAMIN K; COTRIMOXAZOLE; DOXYCYCLINE; LEVOFLOXACIN; PREDNISONE; VITAMIN K GROUP; WARFARIN;

ARTICLE; DRUG ANTAGONISM; DRUG POTENTIATION; FOLLOW UP; FOOD INTAKE; HUMAN; INTERNATIONAL NORMALIZED RATIO; NOMOGRAM; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; PROBABILITY; THROMBOEMBOLISM; TREATMENT RESPONSE;

ANTICOAGULANTS; HUMANS; INTERNATIONAL NORMALIZED RATIO; NOMOGRAMS; VITAMIN K; WARFARIN;

EID: 84872109570     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0032-1324713     Document Type: Article

References (50)

1. Holbrook A., Schulman S., Witt D. M., et al. American College of Chest Physicians. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest: 2012; 141 e152S e184S
2. Rose A. J., Ozonoff A., Berlowitz D. R., Henault L. E., Hylek E. M. Warfarin dose management affects INR control. J Thromb Haemost: 2009; 7 1 94 101
3. Schulman S., Melinyshyn A., Ennis D., Rudd-Scott L. Single-dose adjustment versus no adjustment of warfarin in stably anticoagulated patients with an occasional international normalized ratio (INR) out of range. Thromb Res: 2010; 125 5 393 397
4. Banet G. A., Waterman A. D., Milligan P. E., Gatchel S. K., Gage B. F. Warfarin dose reduction vs watchful waiting for mild elevations in the international normalized ratio. Chest: 2003; 123 2 499 503
5. Fihn S. D., McDonell M. B., Vermes D., et al. National Consortium of Anticoagulation Clinics. A computerized intervention to improve timing of outpatient follow-up: a multicenter randomized trial in patients treated with warfarin. J Gen Intern Med: 1994; 9 3 131 139
6. Ansell J., Hirsh J., Hylek E., et al. American College of Chest Physicians. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest: 2008; 133 160S 198S
7. Heneghan C., Ward A., Perera R., et al. Self-Monitoring Trialist Collaboration. Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. Lancet: 2012; 379 9813 322 334
8. Matchar D. B., Jacobson A., Dolor R., et al. THINRS Executive Committee and Site Investigators. Effect of home testing of international normalized ratio on clinical events. N Engl J Med: 2010; 363 17 1608 1620
9. Rose A. J., Hylek E. M., Berlowitz D. R., Ash A. S., Reisman J. I., Ozonoff A. Prompt repeat testing after out-of-range INR values: a quality indicator for anticoagulation care. Circ Cardiovasc Qual Outcomes: 2011; 4 3 276 282
10. Rose A. J., Ozonoff A., Berlowitz D. R., Ash A. S., Reisman J. I., Hylek E. M. Reexamining the recommended follow-up interval after obtaining an in-range international normalized ratio value: results from the Veterans Affairs study to improve anticoagulation. Chest: 2011; 140 2 359 365
11. Lidstone V., Janes S., Stross P. INR: intervals of measurement can safely extend to 14 weeks. Clin Lab Haematol: 2000; 22 5 291 293
12. Pengo V., Barbero F., Biasiolo A., Pegoraro C., Cucchini U., Iliceto S. A comparison between six- and four-week intervals in surveillance of oral anticoagulant treatment. Am J Clin Pathol: 2003; 120 6 944 947
13. Rose A. J., Ozonoff A., Henault L. E., Hylek E. M. Warfarin for atrial fibrillation in community-based practise. J Thromb Haemost: 2008; 6 10 1647 1654
14. Schulman S., Parpia S., Stewart C., Rudd-Scott L., Julian J. A., Levine M. Warfarin dose assessment every 4 weeks versus every 12 weeks in patients with stable international normalized ratios: a randomized trial. Ann Intern Med: 2011; 155 10 653 659, W201-3
15. Witt D. M., Delate T., Clark N. P., et al. Warfarin Associated Research Projects and other EnDeavors (WARPED) Consortium. Outcomes and predictors of very stable INR control during chronic anticoagulation therapy. Blood: 2009; 114 5 952 956
16. Witt D. M., Delate T., Clark N. P., et al. Warped Consortium. Twelve-month outcomes and predictors of very stable INR control in prevalent warfarin users. J Thromb Haemost: 2010; 8 4 744 749
17. Ageno W., Turpie A. G. A randomized comparison of a computer-based dosing program with a manual system to monitor oral anticoagulant therapy. Thromb Res: 1998; 91 5 237 240
18. Manotti C., Moia M., Palareti G., Pengo V., Ria L., Dettori A. G. Effect of computer-aided management on the quality of treatment in anticoagulated patients: a prospective, randomized, multicenter trial of APROAT (Automated PRogram for Oral Anticoagulant Treatment). Haematologica: 2001; 86 10 1060 1070
19. Marco F., Sedano C., Bermúdez A., López-Duarte M., Fernández-Fontecha E., Zubizarreta A. A prospective controlled study of a computer-assisted acenocoumarol dosage program. Pathophysiol Haemost Thromb: 2003; 33 2 59 63
20. Mitra R., Marciello M. A., Brain C., Ahangar B., Burke D. T. Efficacy of computer-aided dosing of warfarin among patients in a rehabilitation hospital. Am J Phys Med Rehabil: 2005; 84 6 423 427
21. Poller L., Shiach C. R., MacCallum P. K., et al. Multicentre randomised study of computerised anticoagulant dosage. European Concerted Action on Anticoagulation. Lancet: 1998; 352 9139 1505 1509
22. Poller L., Keown M., Ibrahim S., et al. An international multicenter randomized study of computer-assisted oral anticoagulant dosage vs. medical staff dosage. J Thromb Haemost: 2008; 6 6 935 943
23. Vadher B. D., Patterson D. L., Leaning M. Comparison of oral anticoagulant control by a nurse-practitioner using a computer decision-support system with that by clinicians. Clin Lab Haematol: 1997; 19 3 203 207
24. Nieuwlaat R., Barker L., Kim Y. K., et al. Underuse of evidence-based warfarin dosing methods for atrial fibrillation patients. Thromb Res: 2010; 125 4 e128 e131
25. Holbrook A. M., Pereira J. A., Labiris R., et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med: 2005; 165 10 1095 1106
26. Ahmed A., Stephens J. C., Kaus C. A., Fay W. P. Impact of preemptive warfarin dose reduction on anticoagulation after initiation of trimethoprim-sulfamethoxazole or levofloxacin. J Thromb Thrombolysis: 2008; 26 1 44 48
27. Baglin T. Avoiding overanticoagulation: knowing your antibiotics. Thromb Haemost: 2002; 88 5 703 704
28. Dowd M. B., Vavra K. A., Witt D. M., Delate T., Martinez K. Empiric warfarin dose adjustment with prednisone therapy. A randomized, controlled trial. J Thromb Thrombolysis: 2011; 31 4 472 477
29. Dowd M. B., Kippes K. A., Witt D. M., Delate T., Martinez K. A randomized controlled trial of empiric warfarin dose reduction with the initiation of doxycycline therapy. Thromb Res: 2012; 130 152 154
30. Kim K. H., Choi W. S., Lee J. H., Lee H., Yang D. H., Chae S. C. Relationship between dietary vitamin K intake and the stability of anticoagulation effect in patients taking long-term warfarin. Thromb Haemost: 2010; 104 4 755 759
31. Rombouts E. K., Rosendaal F. R., Van Der Meer F. J. Daily vitamin K supplementation improves anticoagulant stability. J Thromb Haemost: 2007; 5 10 2043 2048
32. Sconce E., Avery P., Wynne H., Kamali F. Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin. Blood: 2007; 109 6 2419 2423
33. Gebuis E. P., Rosendaal F. R., van Meegen E., van der Meer F. J. Vitamin K1 supplementation to improve the stability of anticoagulation therapy with vitamin K antagonists: a dose-finding study. Haematologica: 2011; 96 4 583 589
34. van Walraven C., Jennings A., Oake N., Fergusson D., Forster A. J. Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest: 2006; 129 5 1155 1166
35. Chan F. W., Wong R. S., Lau W. H., Chan T. Y., Cheng G., You J. H. Management of Chinese patients on warfarin therapy in two models of anticoagulation service - a prospective randomized trial. Br J Clin Pharmacol: 2006; 62 5 601 609
36. Wilt V. M., Gums J. G., Ahmed O. I., Moore L. M. Outcome analysis of a pharmacist-managed anticoagulation service. Pharmacotherapy: 1995; 15 6 732 739
37. Lalonde L., Martineau J., Blais N., et al. Is long-term pharmacist-managed anticoagulation service efficient? A pragmatic randomized controlled trial. Am Heart J: 2008; 156 1 148 154
38. Wilson S. J., Wells P. S., Kovacs M. J., et al. Comparing the quality of oral anticoagulant management by anticoagulation clinics and by family physicians: a randomized controlled trial. CMAJ: 2003; 169 4 293 298
39. Garcia-Alamino J. M., Ward A. M., Alonso-Coello P., et al. Self-monitoring and self-management of oral anticoagulation. Cochrane Database Syst Rev: 2010; 4 4 CD003839
40. Bloomfield H. E., Krause A., Greer N., et al. Meta-analysis: effect of patient self-testing and self-management of long-term anticoagulation on major clinical outcomes. Ann Intern Med: 2011; 154 7 472 482
41. Connock M., Stevens C., Fry-Smith A., et al. Clinical effectiveness and cost-effectiveness of different models of managing long-term oral anticoagulation therapy: a systematic review and economic modelling. Health Technol Assess: 2007; 11 38 iii iv, ix-66
42. Heneghan C., Alonso-Coello P., Garcia-Alamino J. M., Perera R., Meats E., Glasziou P. Self-monitoring of oral anticoagulation: a systematic review and meta-analysis. Lancet: 2006; 367 9508 404 411
43. McCahon D., Murray E. T., Jowett S., et al. Patient self-management of oral anticoagulation in routine care in the UK. J Clin Pathol: 2007; 60 11 1263 1267
44. Brown A., Wells P., Jaffey J., et al. Point-of-care monitoring devices for long-term oral anticoagulation therapy: clinical and cost effectiveness [Technology report no 72]. Ottawa Canadian Agency for Drugs and Technologies in Health: 2007
45. Jowett S., Bryan S., Murray E., et al. Patient self-management of anticoagulation therapy: a trial-based cost-effectiveness analysis. Br J Haematol: 2006; 134 6 632 639
46. Crowther M. A., Julian J., McCarty D., et al. Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial. Lancet: 2000; 356 9241 1551 1553
47. Crowther M. A., Ageno W., Garcia D., et al. Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial. Ann Intern Med: 2009; 150 5 293 300
48. Patel R. J., Witt D. M., Saseen J. J., Tillman D. J., Wilkinson D. S. Randomized, placebo-controlled trial of oral phytonadione for excessive anticoagulation. Pharmacotherapy: 2000; 20 10 1159 1166
49. Guyatt G. H., Norris S. L., Schulman S., et al. American College of Chest Physicians. Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest: 2012; 141 53S 70S
50. Wallentin L., Yusuf S., Ezekowitz M. D., et al. RE-LY investigators. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet: 2010; 376 9745 975 983